Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance / A071702

Trial Overview

Official Title

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma

 

Study Purpose

To determine whether the combination of ipilimumab and nivolumab increases the tumor response rate in patients with hypermutated recurrent glioblastoma

Diagnosis

Glioblastoma IDH-wildtype CNS WHO grade 4 Astrocytoma, IDH-mutant CNS WHO grade 4

Eligibility

First or second recurrence, must have measurable disease, no requirement of steroid to manage symptoms, certain previous treatment may make the patient ineligible to participate

 

Intervention

Ipilimumab and Nivolumab given for 4 cycles followed by single agent nivolumab.  Treatment continues for as long as the patient is tolerating the drugs and the cancer is controlled

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT04145115?term=A071702&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Gender
Male or Female
Age
19 years and over
Enrollment Status
Suspended
Phase
Phase II
Methodist Health System Trial Code
A071702